Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Cut to $1.75 by Analysts at Guggenheim

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective cut by analysts at Guggenheim from $3.00 to $1.75 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on ADAP. StockNews.com started coverage on shares of Adaptimmune Therapeutics in a research note on Friday, March 21st. They issued a “buy” rating for the company. Mizuho lowered their target price on Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Scotiabank reduced their price target on Adaptimmune Therapeutics from $3.15 to $1.40 and set a “sector outperform” rating for the company in a report on Friday, March 21st. Finally, Wells Fargo & Company dropped their price objective on Adaptimmune Therapeutics from $2.00 to $1.50 and set an “equal weight” rating on the stock in a report on Friday, March 21st. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Adaptimmune Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $1.93.

Adaptimmune Therapeutics Stock Down 1.6 %

Adaptimmune Therapeutics stock opened at $0.25 on Wednesday. The firm has a market capitalization of $62.95 million, a price-to-earnings ratio of -1.12 and a beta of 2.52. Adaptimmune Therapeutics has a fifty-two week low of $0.25 and a fifty-two week high of $1.65. The stock’s fifty day moving average is $0.53 and its two-hundred day moving average is $0.68. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The firm had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. Analysts predict that Adaptimmune Therapeutics will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Long Focus Capital Management LLC increased its holdings in shares of Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after acquiring an additional 7,194,503 shares during the last quarter. Two Seas Capital LP bought a new stake in Adaptimmune Therapeutics during the fourth quarter valued at $7,992,000. Renaissance Technologies LLC raised its holdings in shares of Adaptimmune Therapeutics by 52.5% during the fourth quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock worth $1,361,000 after purchasing an additional 869,949 shares during the period. Rock Springs Capital Management LP lifted its position in shares of Adaptimmune Therapeutics by 2.4% in the 4th quarter. Rock Springs Capital Management LP now owns 2,483,468 shares of the biotechnology company’s stock worth $1,338,000 after buying an additional 58,000 shares during the last quarter. Finally, FMR LLC boosted its holdings in shares of Adaptimmune Therapeutics by 3.0% in the 3rd quarter. FMR LLC now owns 1,740,900 shares of the biotechnology company’s stock valued at $1,655,000 after buying an additional 50,419 shares during the period. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.